TCL Archive Cancer Policy: Coffey Letter Lists Research Initiatives That Justify Increase December 19, 1997
TCL Archive Phase III Trial of Talimogene Laherparepvec Meets Response Rate Primary Endpoint March 29, 2013
TCL Archive Five Year Survival Up To 48 Percent; DeVita Has “No Doubt” It Is Really Over 50 Percent Now December 2, 1983